TNF and inflammatory bowel disease: These data are in line with observations from CLARITY-IBD, in which T-cell responses were not significantly different between patients treated with infliximab and patients treated with vedolizumab following two doses of vaccine,6 but we have not recapitulated the findings of the CORALE study, which showed augmentation of T-cell response in recipients of anti-TNF.32